Hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in heart failure patients: A protocol for systematic review and meta-analysis

Hidekatsu Fukuta¹*, Hiromi Hagiwara², Takeshi Kamiya²

1 Core Laboratory, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan,
2 Department of Medical Innovation, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

* fukuta-h@med.nagoya-cu.ac.jp

Abstract

Background
Anemia is common in heart failure (HF) patients with chronic kidney disease (CKD) and is associated with worse outcomes. Iron supplementation improves symptoms and is associated with reduced risk of hospitalization for HF in iron-deficiency HF patients. However, iron deficiency is present in <30% of anemic HF patients. Erythropoiesis stimulating agents (ESAs) improve symptoms but are associated with increased risk of thromboembolic events in anemic HF patients with CKD. Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors are a new class of agents for the treatment of anemia. These agents work by stabilizing the HIF complex, thereby stimulating endogenous erythropoietin production. We hypothesized that HIF-PH inhibitors may be associated with reduced risk of cardiovascular outcomes compared with ESAs in anemic HF patients with CKD. Accordingly, we aim to perform the meta-analysis of studies on the efficacy and safety of HIF-PH inhibitors compared with ESAs in anemic HF patients with CKD.

Methods
This meta-analysis will include prospective cohort studies and randomized controlled trials on the effect of HIF-PH inhibitors compared with ESAs in anemic HF patients with CKD. Information of studies will be collected from PubMed, Web of Science, Cochrane Library, and ClinicalTrials.gov. The primary outcome will be cardiovascular death. The secondary outcomes will be all-cause death, hospitalization for HF, HF symptoms, exercise capacity, health-related quality of life, and hemoglobin levels.

Discussion
This meta-analysis will evaluate the effect of HIF-PH inhibitors in anemic HF patients with CKD, providing evidence regarding the use of HIF-PH inhibitors in these patients.
Systematic review registration
INPLASY202230103.

Introduction
Heart failure (HF) is a major clinical and public health problem. Despite the significant progress in the treatment of HF, the mortality of HF remains high and, in most recent years, approximately 50% at 5 years [1].

Chronic kidney disease (CKD) is a common comorbidity in HF patients and HF patients with CKD frequently have anemia [2]. In anemic HF patients, inadequate oxygen supply and impaired oxygen use by skeletal muscle during exercise contribute to poor functional capacity [3]. There is substantial evidence that, as a treatment for anemia, iron supplementation improves symptoms, functional capacity, and quality of life and is associated with reduced risk of hospitalization for HF in iron-deficiency HF patients [4–8]. However, iron deficiency is present in <30% of anemic HF patients and the majority of observed anemia in HF patients results from other factors including inadequate erythropoietin production due to renal insufficiency and intrinsic bone marrow defects [3].

The effect of erythropoiesis stimulating agents (ESAs) in anemic HF patients with CKD has been examined in multiple randomized controlled trials (RCTs) [9–11]. Several meta-analyses of RCTs reported that, compared with placebo, ESA-treatment improved symptoms and had a neutral effect on all-cause mortality and hospitalization for HF but increased the risk of thromboembolic events [12, 13].

Hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitors are a new class of agents for the treatment of anemia [2, 14]. These agents work by stabilizing the HIF complex, thereby stimulating endogenous erythropoietin production. HIF-PH inhibitors improve iron mobilization to the bone marrow. By inducing considerably lower but more consistent blood erythropoietin levels than ESAs, HIF-PH inhibitors may be associated with fewer adverse cardiovascular effects at comparable hemoglobin levels. Several case reports have reported that HIF-PH inhibitors improved anemia without significant adverse events in HF patients [15, 16]. Although there are several on-going prospective studies on the effect of HIF-PH inhibitors in anemic HF patients with CKD (ClinicalTrials.gov: NCT05053893; UMIN Clinical Trials Registry: 000041651) [17], there is no evidence as to the effect in these patients. We hypothesized that HIF-PH inhibitors may be associated with reduced risk of cardiovascular outcomes compared with ESAs in anemic HF patients with CKD. Accordingly, we aim to perform the meta-analysis of studies on the efficacy and safety of HIF-PH inhibitors compared with ESAs in anemic HF patients with CKD.

Methods
This study has been registered on International Platform of Registered Systematic Review and Meta-analysis Protocols with registration number of INPLASY202230103 (https://www.doi.org/10.37766/inplasy2022.3.0103). This protocol for meta-analysis will be performed according to the Preferred Reporting Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) statement [18].

Search strategy
The electronic databases for literature search will include PubMed, Web of Science, Cochrane Library, and ClinicalTrials.gov. For search of the eligible studies, the following keywords and
Medical Subject Heading will be used: hypoxia-inducible factor prolyl hydroxylase inhibitor(s), roxadustat, daprodustat, vadadustat, molidustat, desidustat, enarodustat, and heart failure. Only articles published in the English language will be included.

**Study design**
Prospective cohort studies and RCTs will be included. Retrospective cohort and case–control studies will be excluded.

**Selection criteria**
Inclusion criteria for this meta-analysis included: (1) included HF patients with anemia and CKD; (2) prospective cohort studies or RCTs; (3) administration of HIF-PH inhibitors; (4) compared with ESAs; and (5) assessed cardiovascular death, all-cause death, hospitalization for HF, HF symptoms, exercise capacity, health-related quality of life, or hemoglobin levels.

**Outcomes**
The primary outcome will be cardiovascular death. The secondary outcomes will be all-cause death, hospitalization for HF, HF symptoms, exercise capacity (6-minute walk distance), health-related quality of life, and hemoglobin levels.

**Data extraction**
Information on the study and patient characteristics, methodological quality, intervention strategies, and clinical outcomes will be systematically extracted separately by 2 reviewers. Disagreements will be resolved by consensus. We will contact the corresponding author of eligible studies when insufficient information is available to perform our meta-analysis.

**Quality assessment**
The Cochrane Risk of Bias tool will be used to assess quality of RCTs included [19]. The quality of prospective cohort studies will be evaluated by Newcastle-Ottawa Scale tool (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp). The quality of evidence for the outcomes will be evaluated by use of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system [20]. The quality of evidence will be evaluated across the domains of risk of bias, consistency, directness, precision, and publication bias.

**Meta-analysis sample size calculation**
We will determine the required meta-analysis sample size as previously reported [21]. Briefly, after 5 studies report the results of the primary endpoint (cardiovascular death), we will determine the required meta-analysis information size for detecting a reported relative risk reduction in HIF-PH inhibitors group (the median relative risk reduction across trials). We will calculate the information size required to yield meta-analytic evidence based on an alpha = 5% significance level, and beta = 20% (80% power). To evaluate if the observed effects in the two treatments groups differ significantly, we will use a standardized test statistic (Z-statistic) which can be transformed to a P-value. Z-statistics that lie outside the interval $-1.96$ to $1.96$ correspond to P-values smaller than 0.05. The monitoring boundaries will be applied every time one or more studies are added up until the point where the number of patients in the meta-analysis surpasses the required meta-analysis information size.

If the required meta-analysis sample size is not available, a systematic narrative synthesis will be provided with information presented in the text and tables to summarize and explain...
the characteristics and findings of the included studies. The narrative synthesis will explore the relationship and findings both within and between the included studies, in compliance with the guidance from the Centre for Reviews and Dissemination [18].

**Statistical analysis**

For morbidity and mortality, hazard ratios will be pooled. For continuous outcomes, the effect size for the intervention will be calculated by the difference between the means of the intervention and control groups at the end of the intervention. If the outcome is measured on the same scale, the weighted mean difference and 95% confidence interval (CI) will be calculated. Otherwise, the standardized mean difference and 95% CI will be calculated. For each outcome, heterogeneity will be assessed using the Cochran’s Q and $I^2$ statistic; for the Cochran’s Q and $I^2$ statistic, a p value of <0.1 and $I^2>50\%$, will be considered significant, respectively. When there is significant heterogeneity, the data will be pooled using a random-effects model, otherwise a fixed-effects model will be used. Publication bias will be assessed graphically using a funnel plot and mathematically using Egger test. For these analyses, Comprehensive Meta Analysis Software version 2 (Biostat, Englewood, NJ, USA) and STATA 16 software (Stata Corp LP, TX, USA) will be used.

**Sensitivity analysis**

Subgroup analysis stratified by study design (RCT or prospective cohort study) will be performed. Meta-regression will be used to determine whether the effect of HIF-PH inhibitors will be confounded by baseline clinical characteristics such as age, sex, New York Heart Association functional class, CKD stage, and hemoglobin levels.

**Ethical issues**

This meta-analysis is a literature study. Ethical approval is not required because this meta-analysis will not involve any subject directly.

**Discussion**

In the recent guidelines, HIF-PH inhibitors are recommended as alternatives to ESAs in correcting and maintaining hemoglobin level for renal anemia in CKD patients [22]. However, there is no evidence as to the efficacy and safety of HIF-PH inhibitors compare with ESAs in anemic HF patients with CKD.

Several experimental studies have reported that HIF-PH inhibitors have advantages over ESAs. Specifically, it is suggested that exogenous erythropoietin generated by ESAs can largely increase C-terminal fibroblast growth factor 23 (FGF23) levels [23], which is significantly associated with left ventricular hypertrophy and an increased risk of mortality. In contrast, HIF-PH inhibitors have been reported to decrease FGF23 levels in an animal model of CKD [24]. Furthermore, HIF-PH inhibitors have been reported to reduce myocardial ischemia reperfusion injury in mice [25].

To the best of our knowledge, this is the first meta-analysis protocol on the effect of HIF-PH inhibitors in anemic HF patients with CKD. The results will evaluate whether HIF-PH inhibitors are beneficial for anemic HF patients with CKD, providing evidence regarding the use of HIF-PH inhibitors in these patients.

**Author Contributions**

**Conceptualization:** Hidekatsu Fukuta.
Data curation: Hiromi Hagiwara.
Funding acquisition: Hidekatsu Fukuta.
Methodology: Hidekatsu Fukuta, Hiromi Hagiwara, Takeshi Kamiya.
Supervision: Takeshi Kamiya.
Writing – original draft: Hidekatsu Fukuta, Hiromi Hagiwara, Takeshi Kamiya.
Writing – review & editing: Hidekatsu Fukuta, Hiromi Hagiwara, Takeshi Kamiya.

References
1. Roger VL. Epidemiology of Heart Failure: A Contemporary Perspective. Circ Res 2021; 128:1421–1434. https://doi.org/10.1161/CIRCRESAHA.121.318172 PMID: 33983838
2. McCullough PA. Anemia of cardiorenal syndrome. Kidney Int Suppl (2011) 2021; 11:35–45. https://doi.org/10.1016/j.kisu.2020.12.001 PMID: 3777494
3. Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006; 113:2454–2461. https://doi.org/10.1161/CIRCULATIONAHA.105.583666 PMID: 16717164
4. Okonko DO, Grzeslo A, Witkowski T et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008; 51:103–112. https://doi.org/10.1016/j.jacc.2007.09.036 PMID: 18191732
5. Anker SD, Comin Colet J, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361:2436–2448. https://doi.org/10.1056/NEJMoa0908355 PMID: 19920054
6. Beck-da-Silva L, Piardi D, Soder S et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol 2013; 168:3439–3442. https://doi.org/10.1016/j.ijcard.2013.04.181 PMID: 23680589
7. Ponikowski P, van Veldhuisen DJ, Comin-Colet J et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015; 36:657–668.
8. Jankowska EA, Tkaczyzyn M, Suchocki T et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail 2016; 18:786–795. https://doi.org/10.1002/ejhf.473 PMID: 26821594
9. Swedberg K, Young JB, Anand IS et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013; 368:1210–1219. https://doi.org/10.1056/NEJMoai1214865 PMID: 23473338
10. van Veldhuisen DJ, Dickstein K, Cohen-Solal A et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anemia. Eur Heart J 2007; 28:2208–2216. https://doi.org/10.1093/eurheartj/ehm328 PMID: 17681958
11. Ghali JK, Anand IS, Abraham WT et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008; 117:526–535. https://doi.org/10.1161/CIRCULATIONAHA.107.698514 PMID: 18195176
12. Kang J, Park J, Lee JM et al. The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: A meta-analysis of randomized clinical trials. Int J Cardiol 2016; 218:12–22. https://doi.org/10.1016/j.ijcard.2016.04.187 PMID: 27209352
13. Zhang H, Zhang P, Zhang Y et al. Effects of erythropoiesis-stimulating agents on heart failure patients with anaemia: a meta-analysis. Postepy Kardiologii Interwencyjnej 2016; 12:247–253. https://doi.org/10.5114/pki.2016.61647 PMID: 27265688
14. Gupta N, Wish JB. Hypoxia-Inducible Factor Prolly Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. Am J Kidney Dis 2017; 69:815–826. https://doi.org/10.1053/j.ajkd.2016.12.011 PMID: 28242135
15. Imamura T, Horii M, Tanaka S, Kinugawa K. Impact of Hypoxia-Inducible Factor Prolly Hydroxylase Inhibitor on Heart Failure with Preserved Ejection Fraction. Medicina (Kaunas) 2021; 57. https://doi.org/10.3390/medicina57121319 PMID: 34946264
16. Imamura T, Ueno Y, Kinugawa K. Impact of Hypoxia-Inducible Factor Prolly Hydroxylase Inhibitor on Renal Function in Patient with Heart Failure. J Cardiovasc Dev Dis 2021; 8. https://doi.org/10.3390/jcdd8120189 PMID: 34940544
17. Wen Y, Xu Y, Tian H et al. Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome: Protocol of a Randomized Controlled Trial. Front Med (Lausanne) 2022; 9:783387. https://doi.org/10.3389/fmed.2022.783387 PMID: 35445052

18. Moher D, Shamseer L, Clarke M et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4:1. https://doi.org/10.1186/2046-4053-4-1 PMID: 25554246

19. Higgins JP, Altman DG, Gotzsche PC et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343:d5928. https://doi.org/10.1136/bmj.d5928 PMID: 22008217

20. Guyatt GH, Oxman AD, Schunemann HJ et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011; 64:380–382. https://doi.org/10.1016/j.jclinepi.2010.09.011 PMID: 21185693

21. Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clin Epidemiol 2010; 2:57–66. https://doi.org/10.2147/clep.s9242 PMID: 20865104

22. Yap DYH, McMahon LP, Hao CM et al. Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors. Nephrology (Carleton) 2021; 26:105–118. https://doi.org/10.1111/nep.13835 PMID: 33222343

23. Eisenga MF, Emans ME, van der Putten K et al. Epoetin Beta and C-Terminal Fibroblast Growth Factor 23 in Patients With Chronic Heart Failure and Chronic Kidney Disease. J Am Heart Assoc 2019; 8:e011130. https://doi.org/10.1161/JAHA.118.011130 PMID: 31423921

24. Noonan ML, Clinkenbeard EL, Ni P et al. Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) lowers FGF23 in a model of chronic kidney disease (CKD). Physiol Rep 2020; 8:e14434. https://doi.org/10.14814/phy2.14434 PMID: 32476270

25. Deguchi H, Ikeda M, Ide T et al. Roxadustat Markedly Reduces Myocardial Ischemia Reperfusion Injury in Mice. Circ J 2020; 84:1028–1033. https://doi.org/10.1253/circj.CJ-19-1039 PMID: 32213720